Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:KRYS NASDAQ:PRAX NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$121.40-0.6%$116.73$5.59▼$148.83$9.63B0.841.10 million shs586,766 shsKRYSKrystal Biotech$309.05-1.2%$264.46$122.80▼$315.17$9.11B0.5298,073 shs133,708 shsPRAXPraxis Precision Medicines$333.23+0.4%$317.26$35.21▼$356.00$9.29B2.76460,364 shs183,727 shsZLABZai Lab$19.38-1.1%$20.22$15.96▼$44.34$2.20B0.85760,831 shs321,688 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.50%+3.84%-3.18%+2.48%+1,720.12%KRYSKrystal Biotech+2.35%+17.61%+20.80%+15.58%+136.62%PRAXPraxis Precision Medicines+0.54%+2.35%+4.96%+3.54%+765.22%ZLABZai Lab+5.32%-9.05%-5.27%+0.20%-33.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$121.40-0.6%$116.73$5.59▼$148.83$9.63B0.841.10 million shs586,766 shsKRYSKrystal Biotech$309.05-1.2%$264.46$122.80▼$315.17$9.11B0.5298,073 shs133,708 shsPRAXPraxis Precision Medicines$333.23+0.4%$317.26$35.21▼$356.00$9.29B2.76460,364 shs183,727 shsZLABZai Lab$19.38-1.1%$20.22$15.96▼$44.34$2.20B0.85760,831 shs321,688 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax-0.50%+3.84%-3.18%+2.48%+1,720.12%KRYSKrystal Biotech+2.35%+17.61%+20.80%+15.58%+136.62%PRAXPraxis Precision Medicines+0.54%+2.35%+4.96%+3.54%+765.22%ZLABZai Lab+5.32%-9.05%-5.27%+0.20%-33.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.93Moderate Buy$137.1511.97% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.113.81% UpsidePRAXPraxis Precision Medicines 3.00Buy$591.8379.41% UpsideZLABZai Lab 2.63Moderate Buy$45.83134.84% UpsideCurrent Analyst Ratings BreakdownLatest ZLAB, ABVX, PRAX, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$420.005/8/2026PRAXPraxis Precision Medicines WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$130.00 ➝ $166.005/8/2026PRAXPraxis Precision Medicines BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$843.005/8/2026ZLABZai Lab CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$47.00 ➝ $44.005/7/2026PRAXPraxis Precision Medicines Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/24/2026ZLABZai Lab Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026ABVXAbivax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$437.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/AKRYSKrystal Biotech$389.13M23.65$7.44 per share41.94$42.06 per share7.42PRAXPraxis Precision Medicines$8.55M1,075.66N/AN/A$34.85 per share9.47ZLABZai Lab$460.16M4.81N/AN/A$6.39 per share3.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.37N/AN/AN/AN/A-146.43%-88.69%5/25/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4841.7429.68N/A53.92%19.25%17.62%N/APRAXPraxis Precision Medicines-$303.27M-$13.37N/AN/AN/AN/A-60.25%-54.81%N/AZLABZai Lab-$175.54M-$1.62N/AN/AN/A-39.29%-24.32%-15.52%N/ALatest ZLAB, ABVX, PRAX, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/25/2026Q1 2026ABVXAbivax-$0.9359N/AN/AN/A$0.40 millionN/A5/7/2026Q1 2026PRAXPraxis Precision Medicines-$3.58-$3.20+$0.38-$3.20$0.10 millionN/A5/7/2026Q1 2026ZLABZai Lab-$0.5262-$0.46+$0.0662-$0.50$108.43 million$99.61 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million4/1/2026Q1 2026ZLABZai LabN/A-$0.50N/A-$0.50N/A$99.61 million3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million2/26/2026Q4 2025ZLABZai Lab-$0.44-$0.46-$0.02-$0.50$122.67 million$127.60 million2/19/2026Q4 2025PRAXPraxis Precision Medicines-$3.00-$3.50-$0.50-$3.50$0.26 millionN/A2/17/2026Q4 2025KRYSKrystal Biotech$1.62$1.70+$0.08$1.70$105.30 million$107.11 million2/14/2026Q4 2025ABVXAbivaxN/A-$1.20N/A-$1.20N/A$0.52 million2/14/2026Q4 2025ZLABZai LabN/A-$0.50N/A-$0.50N/A$127.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.758.75KRYSKrystal BiotechN/A9.469.06PRAXPraxis Precision MedicinesN/A10.2210.22ZLABZai LabN/A2.402.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%KRYSKrystal Biotech86.29%PRAXPraxis Precision Medicines67.84%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/AKRYSKrystal Biotech13.10%PRAXPraxis Precision Medicines2.70%ZLABZai Lab4.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.29 millionN/ANot OptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionablePRAXPraxis Precision Medicines11027.88 million27.13 millionOptionableZLABZai Lab1,784113.41 million107.88 millionOptionableZLAB, ABVX, PRAX, and KRYS HeadlinesRecent News About These CompaniesZai Lab Limited 2026 Q1 - Results - Earnings Call PresentationMay 11 at 7:20 PM | seekingalpha.comZai Lab Limited (NASDAQ:ZLAB) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 11 at 1:21 PM | finance.yahoo.comZai Lab wins FDA fast track status for cancer drug Zocilurtatug PelitecanMay 11 at 8:21 AM | msn.comZai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)May 11 at 7:00 AM | businesswire.comZai Lab Q1 Earnings Call HighlightsMay 9 at 5:04 AM | marketbeat.comZai Lab (NASDAQ:ZLAB) Given New $44.00 Price Target at CitigroupMay 8, 2026 | marketbeat.comZai Lab Limited (ZLAB) Q1 2026 Earnings Call TranscriptMay 7, 2026 | seekingalpha.comZai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comZai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to SayMay 7, 2026 | zacks.comZai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesMay 7, 2026 | finance.yahoo.comZai Lab (ZLAB) Expected to Announce Earnings on ThursdayApril 30, 2026 | marketbeat.comAssessing Zai Lab (ZLAB) Valuation After Recent Share Price Momentum And Analyst Target ResetApril 29, 2026 | finance.yahoo.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesApril 26, 2026 | marketbeat.comZai Lab Showcases 54% Brain Metastases Response for ZL-1310 ADC in SCLC at AACR Investor CallApril 26, 2026 | marketbeat.comZai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases - SlideshowApril 22, 2026 | seekingalpha.comZai Lab (NASDAQ:ZLAB) Trading Down 5.2% - Here's What HappenedApril 22, 2026 | marketbeat.comZai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026April 22, 2026 | businesswire.comZai Lab Limited (ZLAB) Discusses Intracranial Activity of a New Therapy in Small Cell Lung Cancer With Brain Metastases TranscriptApril 20, 2026 | seekingalpha.comZai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic DiseasesApril 18, 2026 | businesswire.comZai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and ...April 18, 2026 | finance.yahoo.comZai Lab stock rises on positive trial data for cancer drugApril 18, 2026 | in.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZLAB, ABVX, PRAX, and KRYS Company DescriptionsAbivax NASDAQ:ABVX$121.40 -0.73 (-0.60%) As of 03:04 PM Eastern This is a fair market value price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Krystal Biotech NASDAQ:KRYS$308.79 -4.09 (-1.31%) As of 03:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Praxis Precision Medicines NASDAQ:PRAX$331.57 -0.24 (-0.07%) As of 03:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Zai Lab NASDAQ:ZLAB$19.38 -0.21 (-1.09%) As of 03:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas On Holdings Sets Up for Marathon Rally: New Highs Are Coming Shake Shack Stock Gets Shaken After Earnings Miss Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe? MP Materials Is Quietly Building a Rare Earth Powerhouse The DRAM Shake-Up: Samsung Stumbles, Micron Chases $1000 Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
